Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM0JETC)

Drug Name
Genistein Drug Info
Synonyms
Bonistein; GEN; Genestein; Genisteol; Genisterin; Prunetol; Sophoricol; Differenol A; G 6649; G10000; IN1327; NPI 031L; STO514; TNP00151; GENISTEIN (ENDOCRINE DISRUPTER); Lactoferrin-genistein; PTI G4660 (Genistein); PTI-G4660; SIPI 807-1; C.I. 75610; SIPI-9764-I; ENDOCRINE DISRUPTOR (GENISTEIN) (SEE ALSO GENISTEIN (446-72-0)); 4 inverted exclamation marka,5,7-Trihydroxyisoflavone; ,5,7-Trihydroxyisoflavone; 4',5, 7-Trihydroxyisoflavone; 4',5,7-Trihydroxy isoflavone; 4',5,7-Trihydroxyisoflavone; 4,5,7-Trihydroxyiso-flavone; 4,6,7-Trihydroxyisoflavone; 5,7,4'-Trihydroxyisoflavone; 5,7-Dihydroxy-3-(4-hydroxyphenyl)-4-benzopyrone; 5,7-Dihydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; 5,7-dihydroxy-3-(4-hydroxyphenyl)-4H-chromen-4-one; 5,7-dihydroxy-3-(4-hydroxyphenyl)chromen-4-one
Cross-matching ID
PubChem CID
5280961
ChEBI ID
CHEMBL44
CAS Number
CAS 446-72-0
TTD Drug ID
D0L4FS
VARIDT Drug ID
DR00641
INTEDE Drug ID
DR0768

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Proteasome 2.34 0.00e+0 44/46 (95.65%) PSMB9;PSMA4;PSMC6;...
Oxidative phosphorylation 2.26 0.00e+0 93/133 (69.92%) NDUFB5;COX7A1;NDUFS3;...
DNA replication 2.07 0.00e+0 34/36 (94.44%) PCNA;RPA3;RFC4;...
Huntington disease 2.06 0.00e+0 233/306 (76.14%) SLC25A4;CASP3;TBPL1;...
Amyotrophic lateral sclerosis 2.02 1.51e-3 267/364 (73.35%) CASP3;NDUFB5;TBK1;...
Parkinson disease 1.94 1.26e-3 176/249 (70.68%) SLC25A4;CASP3;NDUFB5;...
Nucleotide excision repair 1.92 2.16e-3 40/47 (85.11%) PCNA;DDB2;GTF2H5;...
Mismatch repair 1.91 1.89e-3 22/23 (95.65%) PCNA;RPA3;RFC4;...
Valine, leucine and isoleucine degradation 1.89 1.68e-3 42/48 (87.5%) ALDH2;ABAT;ACAD8;...
Ribosome biogenesis in eukaryotes 1.89 1.51e-3 52/108 (48.15%) POP5;IMP3;MPHOSPH10;...
Arginine and proline metabolism 1.82 3.44e-3 39/50 (78%) ALDH2;CKB;GATM;...
Tryptophan metabolism 1.81 4.41e-3 35/42 (83.33%) ALDH2;CAT;IDO1;...
SNARE interactions in vesicular transport 1.79 5.82e-3 19/33 (57.58%) VAMP1;BET1;STX7;...
Thermogenesis 1.75 1.30e-2 173/232 (74.57%) SMARCD3;NDUFB5;COX7A1;...
Base excision repair 1.73 1.82e-2 29/33 (87.88%) PCNA;POLB;PARP1;...
Propanoate metabolism 1.73 1.70e-2 30/34 (88.24%) ABAT;DLD;PCCA;...
Taurine and hypotaurine metabolism 1.71 2.00e-2 8/11 (72.73%) ADO;CDO1;CSAD
Circadian rhythm 1.69 2.23e-2 26/31 (83.87%) BHLHE40;BHLHE41;PER3;...
Citrate cycle (TCA cycle) 1.68 2.39e-2 30/30 (100%) OGDHL;MDH1;PDHB;...
Type I diabetes mellitus 1.68 2.57e-2 38/43 (88.37%) CPE;HLA-DQA1;FAS;...
Epstein-Barr virus infection 1.65 3.24e-2 189/202 (93.56%) DDB2;CXCL10;CDKN1A;...
Alanine, aspartate and glutamate metabolism 1.63 3.61e-2 27/37 (72.97%) ASS1;ABAT;CPS1;...
Pyruvate metabolism 1.63 3.49e-2 41/47 (87.23%) ALDH2;ALDH9A1;MDH1;...
Butanoate metabolism 1.62 3.75e-2 23/28 (82.14%) BDH2;ABAT;HADH;...
Glycine, serine and threonine metabolism 1.62 3.69e-2 31/40 (77.5%) GATM;PSAT1;ALAS1;...
mRNA surveillance pathway 1.61 3.99e-2 71/98 (72.45%) PPP2R1B;PNN;CLP1;...
GnRH secretion -1.63 4.63e-2 60/64 (93.75%) ARRB2;KCNN4;GNA11;...
Regulation of actin cytoskeleton -1.63 4.61e-2 185/218 (84.86%) GIT1;FGFR1;PPP1R12B;...
Long-term depression -1.63 4.75e-2 55/60 (91.67%) GRM1;GNAS;GNA11;...
AGE-RAGE signaling pathway in diabetic complications -1.63 4.74e-2 97/100 (97%) PIK3R2;SELE;MAPK3;...
Gastric acid secretion -1.64 4.78e-2 63/76 (82.89%) PLCB3;ITPR2;CFTR;...
Fluid shear stress and atherosclerosis -1.66 4.58e-2 123/139 (88.49%) BMP4;PIK3R2;SELE;...
ErbB signaling pathway -1.67 4.16e-2 79/85 (92.94%) NRG1;PAK6;MAPK8;...
Carbohydrate digestion and absorption -1.67 4.38e-2 37/47 (78.72%) PIK3R2;ATP1A1;HKDC1;...
Renal cell carcinoma -1.67 4.63e-2 68/69 (98.55%) PIK3R2;RAPGEF1;MAPK3;...
Yersinia infection -1.69 4.30e-2 120/137 (87.59%) PIP5K1C;GSK3B;MAP2K3;...
Rap1 signaling pathway -1.69 4.49e-2 184/210 (87.62%) GRIN2A;GNAS;INSR;...
Ras signaling pathway -1.72 3.76e-2 201/232 (86.64%) ABL1;RASA3;SHC3;...
Arrhythmogenic right ventricular cardiomyopathy -1.72 3.94e-2 70/77 (90.91%) LEF1;ITGA8;CACNB2;...
Proteoglycans in cancer -1.75 3.45e-2 172/205 (83.9%) TP53;RHOA;GPC1;...
VEGF signaling pathway -1.76 3.42e-2 50/59 (84.75%) PTK2;VEGFA;AKT2;...
Leukocyte transendothelial migration -1.76 3.49e-2 90/114 (78.95%) ROCK2;CTNNA3;MYL12B;...
Parathyroid hormone synthesis, secretion and action -1.76 3.84e-2 98/106 (92.45%) ARHGEF1;BRAF;ADCY3;...
Acute myeloid leukemia -1.76 4.27e-2 66/67 (98.51%) PIK3R2;MPO;MAPK3;...
Sphingolipid signaling pathway -1.78 3.52e-2 106/119 (89.08%) SPHK2;MS4A2;TRADD;...
ECM-receptor interaction -1.80 3.11e-2 80/88 (90.91%) DMP1;COL4A1;COL6A2;...
MAPK signaling pathway -1.84 2.35e-2 272/294 (92.52%) CACNG1;TRADD;STK4;...
Hematopoietic cell lineage -1.88 1.79e-2 90/99 (90.91%) DNTT;IL5RA;IL1B;...
Fc gamma R-mediated phagocytosis -1.92 1.60e-2 79/97 (81.44%) PIP5K1C;PIK3R2;MAPK3;...
Focal adhesion -1.97 8.54e-3 180/201 (89.55%) DIAPH1;MYL5;SHC3;...
Salivary secretion -2.09 0.00e+0 76/93 (81.72%) NOS1;ADCY3;TRPV6;...
Adherens junction -2.14 0.00e+0 63/71 (88.73%) FYN;FGFR1;EP300;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 10uM - 20uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 20uM 6H, 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 6H, 24H
Fibroblast
Nasopharyngeal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
FIBRNPC CVCL_UK07 Homo sapiens 10uM 6H, 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 20uM 6H, 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 0.04uM - 10uM 6H, 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.04uM - 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 0.04uM - 10uM 6H, 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 20uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 1.11uM - 20uM 6H, 24H, 48H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 6H, 24H